GXIN Stock Chart & Stats
$554.68
$0.00(0.00%)
At close: 4:00 PM EDT
$554.68
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$347.84 - $1,649.75
Previous CloseN/A
Volume0.00
Average Volume (3M)140.00
Market Cap
$18.73B
Enterprise Value$3.53K
Total Cash (Recent Filing)$176.21M
Total Debt (Recent Filing)$1.60B
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.28
Shares Outstanding34,540,000
10 Day Avg. Volume365
30 Day Avg. Volume140
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.40
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$514.44Price Target Upside-7.25% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)35.94
Revenue Forecast (FY)$46.32B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthRevenue growth over several years indicates expanding demand for Gerresheimer’s pharmaceutical packaging and drug-delivery products. A larger revenue base can improve scale, deepen customer relationships, and provide a foundation for restoring profitability if operating execution normalizes.
Regulated, Recurring Business ModelGerresheimer supplies regulation-critical packaging and delivery systems that customers repeatedly purchase for approved medicines. Qualification cycles and demanding quality standards can create durable customer relationships, recurring production orders, and meaningful barriers to switching suppliers.
Positive Operating Cash FlowPositive operating cash flow demonstrates that the underlying business continues to convert operations into cash despite the latest-year loss. This provides an internal funding base for required investment and supports financial resilience, although the benefit is reduced by substantial capital and other cash uses.
Bears Say
Sharp Profitability DeteriorationThe swing from sustained historical profitability to a substantial EBIT and net loss is a major deterioration in earnings quality. Unless the causes are reversed, ongoing losses could weaken reinvestment capacity, reduce equity, and make future financial performance more dependent on external funding.
Higher Leverage And Lower EquityHigher debt alongside a materially smaller equity base increases financial risk and reduces balance-sheet flexibility. Greater leverage can constrain investment and capital allocation, while the weaker equity cushion leaves the company less able to absorb further losses or operating disruption.
Persistently Negative Free Cash FlowDeeply negative free cash flow means positive operating cash generation is not covering investment, working-capital needs, or other cash uses. This weakens the company’s ability to fund growth internally and increases reliance on financing at a time when debt is already rising.
Gerresheimer News
GXIN FAQ
What was Gerresheimer AG’s price range in the past 12 months?
Gerresheimer AG lowest stock price was $347.84 and its highest was $1649.75 in the past 12 months.
What is Gerresheimer AG’s market cap?
Gerresheimer AG’s market cap is $18.73B.
When is Gerresheimer AG’s upcoming earnings report date?
Gerresheimer AG’s upcoming earnings report date is Oct 15, 2026 which is in 26 days.
How were Gerresheimer AG’s earnings last quarter?
Gerresheimer AG released its earnings results on Oct 10, 2025. The company reported $13.655 earnings per share for the quarter, missing the consensus estimate of $16.149 by -$2.494.
Is Gerresheimer AG overvalued?
According to Wall Street analysts Gerresheimer AG’s price is currently Overvalued.
Does Gerresheimer AG pay dividends?
Gerresheimer AG does not currently pay dividends.
What is Gerresheimer AG’s EPS estimate?
Gerresheimer AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gerresheimer AG have?
Gerresheimer AG has 34,540,000 shares outstanding.
What happened to Gerresheimer AG’s price movement after its last earnings report?
Gerresheimer AG reported an EPS of $13.655 in its last earnings report, missing expectations of $16.149. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Gerresheimer AG?
Currently, no hedge funds are holding shares in MX:GXIN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gerresheimer Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Gerresheimer AG
Gerresheimer AG, founded in 1864 and based in Düsseldorf, Germany, is a global supplier specializing in the production and sale of packaging solutions and sophisticated drug delivery systems. The company operates through three distinct divisions. Its Plastics & Devices segment provides a variety of drug administration tools, such as inhalers, insulin pen systems, prefillable syringes, and diagnostic systems, for the pharmaceutical, biotech, diagnostics, and medical technology sectors. This division also manufactures plastic containers, closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and related accessories for solid, liquid, and ophthalmic applications, alongside bottles for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging products for the pharmaceutical and cosmetics industries, including infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; and miniature bottles for liquid food, spices, spirits, fragrances, deodorants, skincare, and wellness products. Lastly, the Advanced Technologies division focuses on developing intelligent drug delivery systems, like micro pumps, designed to enable the self-administration of medication for conditions such as Parkinson's disease or heart failure, serving its pharmaceutical and biotech clients.
GXIN Stock 12 Month Forecast
Average Price Target
$514.44
▼(-7.25% Downside)